EW250516P80000
- 5.84
- +1.07+22.43%
Edwards Lifesciences Newsroom
Edwards Lifesciences First Quarter 2025 Earnings: EPS Beats Expectations
What's Driving the Market Sentiment Around Edwards Lifesciences?
Edwards Lifesciences Insider Sold Shares Worth $447,977, According to a Recent SEC Filing
Edwards Lifesciences | 10-Q: Q1 2025 Earnings Report
Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference
Balanced Outlook on Edwards Lifesciences: Navigating FDA Approval and Capacity Constraints
Jefferies Maintains Edwards Lifesciences(EW.US) With Hold Rating
Jefferies Remains a Hold on Edwards Lifesciences (EW)
P/E Ratio Insights for Edwards Lifesciences
Edwards Announces TAVR Receives FDA Approval For Patients With Asymptomatic Severe Aortic Stenosis
Express News | Edwards Tavr Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis
9 Health Care Stocks Whale Activity In Today's Session
Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Edwards Lifesciences (EW) and Gilead Sciences (GILD)
Edwards Lifesciences Reports Robust Q1 2025 Growth
CCORF Maintains Edwards Lifesciences(EW.US) With Hold Rating, Raises Target Price to $75
A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $75 to $90
Express News | Canaccord Genuity Maintains Hold on Edwards Lifesciences, Raises Price Target to $75
Cautious Outlook on Edwards Lifesciences Amid Growth Potential and Market Challenges
Hold Rating on Edwards Lifesciences: Balancing Positive Trends With TAVR Uncertainties